St├ęphane De Lombaert Ph.D.



Dr. De Lombaert joined E-Scape Bio as Head of Chemistry in 2016, bringing along over 25 years of R&D leadership, small molecule drug discovery experience, and a track record of accomplishments leading to the identification of several preclinical and clinical development candidates. Dr. De Lombaert is responsible for devising and implementing the chemical strategies underlying E-Scape Bio's hit-to-lead and lead optimization activities in the field of neurodegenerative diseases.

Most recently, Dr. De Lombaert started Karos Pharmaceuticals where he served as President, Chief Operating Officer, and Head of Chemistry. There, he helped build a successful biotechnology start-up while initiating and overseeing all Chemistry activities related to drug discovery and development, from project inception to Phase 1 clinical trials. These efforts led to the clinical development a novel therapeutic agent for the treatment of pulmonary arterial hypertension. Prior to that, Dr. De Lombaert was Director of Medicinal Chemistry and Distinguished Research Fellow at Boehringer Ingelheim US, where he led several project teams in the area of cardiovascular diseases.

Before that, he was Executive Director of Medicinal Chemistry at Neurogen Corporation, where he spearheaded several lead optimization efforts, seeking innovative approaches for the treatment of obesity, psychiatric disorders, and chronic pain, some of these in collaboration with various big-pharma partners. Prior to Neurogen, Dr. De Lombaert was a project leader at Ciba-Geigy, then Novartis US, in the area of hypertension and kidney diseases. Dr. De Lombaert has co-authored about 60 scientific publications and is an inventor on more than 45 issued patents. Dr. De Lombaert earned his Ph.D. in Chemistry from the Catholic University of Louvain in Belgium and completed post-doctoral research at the University of Virginia and at Colorado State University.